Analyst Price Targets — DTIL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 13, 2026 6:57 pm | Maury Raycroft | Jefferies | $19.00 | $5.67 | StreetInsider | Precision BioSciences Inc. (DTIL) PT Lowered to $19 at Jefferies, but 'near-term setup is attractive' |
| April 1, 2024 7:19 am | Justin Zelin | BTIG | $30.00 | $13.56 | TheFly | Precision BioSciences price target raised to $30 from $2 at BTIG |
| November 10, 2022 10:11 am | — | Goldman Sachs | $1.00 | $1.38 | Benzinga | Goldman Sachs Maintains Neutral on Precision BioSciences, Lowers Price Target to $1 |
Latest News for DTIL
Precision BioSciences (DTIL) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of a loss of $0.21 per share. This compares to a loss of $3.2 per share a year ago.
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced financial results for the fourth quarter and fiscal year ended December 31, 2025, and provided a business update. “2025 was an exceptional year for Precision BioSciences…
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has received two Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent applications relating to the Company's PBGENE-HBV program. The…
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced presentation of new preclinical study data supporting the potential long-term efficacy of PBGENE-DMD. The data presentation took place during a poster session at the…
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the fourth quarter 2025 and provide a business update on March 12, 2026. About Precision BioSciences, Inc. Precision…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DTIL.
U.S. House Trading
No House trades found for DTIL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.